177 related articles for article (PubMed ID: 29296748)
1. Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.
Ho CM; McCarthy PL; Wallace PK; Zhang Y; Fora A; Mellors P; Tario JD; McCarthy BLS; Chen GL; Holstein SA; Balderman SR; Cao X; Paiva B; Hahn T
Blood Adv; 2017 Jun; 1(15):1056-1066. PubMed ID: 29296748
[TBL] [Abstract][Full Text] [Related]
2. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
[No Abstract] [Full Text] [Related]
3. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
4. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
5. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia.
Klyuchnikov E; Badbaran A; Massoud R; Fritsche-Friedland U; Janson D; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2021 Oct; 27(10):841-850. PubMed ID: 34118468
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
9. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
10. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
11. Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.
Lima-Júnior JR; Arruda LCM; Gonçalves MS; Dias JBE; Moraes DA; Covas DT; Simões BP; Oliveira MC; Malmegrim KCR
Rheumatology (Oxford); 2021 Dec; 60(12):5538-5548. PubMed ID: 33724344
[TBL] [Abstract][Full Text] [Related]
12. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation.
Mego M; Gao H; Lee BN; Cohen EN; Tin S; Giordano A; Wu Q; Liu P; Nieto Y; Champlin RE; Hortobagyi GN; Cristofanilli M; Ueno NT; Reuben JM
J Cancer; 2012; 3():369-80. PubMed ID: 23074378
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
[TBL] [Abstract][Full Text] [Related]
15. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.
Arruda LCM; Malmegrim KCR; Lima-Júnior JR; Clave E; Dias JBE; Moraes DA; Douay C; Fournier I; Moins-Teisserenc H; Alberdi AJ; Covas DT; Simões BP; Lansiaux P; Toubert A; Oliveira MC
Blood Adv; 2018 Jan; 2(2):126-141. PubMed ID: 29365321
[TBL] [Abstract][Full Text] [Related]
16. Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation.
Gernert M; Tony HP; Schwaneck EC; Fröhlich M; Schmalzing M
Arthritis Res Ther; 2020 Aug; 22(1):183. PubMed ID: 32771029
[TBL] [Abstract][Full Text] [Related]
17. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
18. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
19. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
[TBL] [Abstract][Full Text] [Related]
20. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
